Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?

Detalhes bibliográficos
Autor(a) principal: Souza, Helano de Paula Gonçalves
Data de Publicação: 2015
Outros Autores: Cavalcante, Francisco Pimentel, Ferreira, José Carlos Lucena de Aguiar, Batista, Rafael Valente, Lima, Marcos Venício Alves
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/759
Resumo: Introduction: Carcinoma in situ accounts for approximately 15% of breast cancers. By definition, it does not exceed the basal membrane, which would imply zero theoretical risk for lymph node metastasis. However, according to the literature, 1-13% of sentinel lymph node biopsies (SNB) in patients with carcinoma ductal in situ (DCIS) are positive. Objective: To determine the prevalence of sentinel lymph node metastasis in patients with DCIS treated surgically at a referral hospital in Northeastern Brazil. Method: Cross-sectional and descriptive study using secondary data obtained from the medical records of patients with breast cancer that underwent surgery at the Cancer Institute of Ceará (ICC) between 2002 and 2012. The data were analyzed with the software Epi Info 7.0. Results: The study population included 746 patients with primary breast tumors, being 106 (14%) of them diagnosed with DCIS on the initial histological examination. Fifty-four patients (51%) underwent mastectomy and 52 (49%) conservative surgery. SNB was performed in 88 (83%) of 106 cases of DCIS, but only one case (1.1%) was positive. During follow-up of the 106 DCIS patients, 2 had local recurrence and 1 had loco regional recurrence. Conclusion: SNB in patients with DCIS alone revealed a low prevalence of lymph node metastasis, matching most studies on the topic. Despite the low morbidity of SNB, the additional financial cost and its negligible impact on therapeutic decision suggest the procedure is not indispensable in this patient population.
id INCA-1_1ffe983e5a5ae3e5392b06b988949ff6
oai_identifier_str oai:rbc.inca.gov.br:article/759
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?¿La Biopsia del Ganglio Linfático Centinela en el Carcinoma Ductal in situ de Mama es Necesaria?É Necessária a Biópsia do Linfonodo Sentinela no Carcinoma Ductal in situ da Mama?Biópsia de Linfonodo SentinelaCarcinoma Ductal de MamaCarcinoma Intraductal não InfiltranteSentinel Lymph Node BiopsyCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingBiopsia del Ganglio Linfático CentinelaCarcinoma Ductal de MamaCarcinoma Intraductal não InfiltranteIntroduction: Carcinoma in situ accounts for approximately 15% of breast cancers. By definition, it does not exceed the basal membrane, which would imply zero theoretical risk for lymph node metastasis. However, according to the literature, 1-13% of sentinel lymph node biopsies (SNB) in patients with carcinoma ductal in situ (DCIS) are positive. Objective: To determine the prevalence of sentinel lymph node metastasis in patients with DCIS treated surgically at a referral hospital in Northeastern Brazil. Method: Cross-sectional and descriptive study using secondary data obtained from the medical records of patients with breast cancer that underwent surgery at the Cancer Institute of Ceará (ICC) between 2002 and 2012. The data were analyzed with the software Epi Info 7.0. Results: The study population included 746 patients with primary breast tumors, being 106 (14%) of them diagnosed with DCIS on the initial histological examination. Fifty-four patients (51%) underwent mastectomy and 52 (49%) conservative surgery. SNB was performed in 88 (83%) of 106 cases of DCIS, but only one case (1.1%) was positive. During follow-up of the 106 DCIS patients, 2 had local recurrence and 1 had loco regional recurrence. Conclusion: SNB in patients with DCIS alone revealed a low prevalence of lymph node metastasis, matching most studies on the topic. Despite the low morbidity of SNB, the additional financial cost and its negligible impact on therapeutic decision suggest the procedure is not indispensable in this patient population.Introducción: Los carcinomas in situ representan aproximadamente el 15% de los cánceres de mama. Por definición no atraviesan la membrana basal, lo que implicaría en un riesgo teórico cero para la metástasis de los ganglios linfáticos. Sin embargo, la literatura muestra tasas que van del 1 al 13% de metástasis en biopsias de ganglios linfáticos centinelas (BLC ) realizadas en pacientes con carcinoma ductal in situ (CDIS). Objetivo: Determinar la prevalencia de metástasis en los ganglios linfáticos centinela en pacientes con CDIS de mama tratadas quirúrgicamente en una institución de referencia en el Nordeste Brasileño. Método: Estudio transversal y descriptivo, utilizando datos secundarios obtenidos de las historias clínicas de los pacientes con cáncer de mama operado en el Instituto del Cáncer de Ceará (ICC) entre los años 2002 al 2012. Los datos fueron analizados mediante el software Epi Info 7.0. Resultados: La población de estudio correspondió a 746 pacientes con tumor primario de mama, 106 (14%) tuvieron como tipo histológico inicial el CDIS. Cincuenta y cuatro pacientes (51%) fueron sometidos a mastectomía y 52 (49%) a cirugía conservadora. La BLC fue realizada en 88 (83%) de los 106 casos de CDIS, mostrando una positividad de metástasis de los ganglios linfáticos en un solo caso (1,1%). Al final del análisis, en los 106 pacientes con CDIS, 2 mostraron recurrencia local, 1 recurrencia locorregional. Conclusión: Las BLC en pacientes con CDIS puro, similar a lo que se encuentra en la literatura, presentan una baja prevalencia de metástasis en los ganglios linfáticos. A pesar de la baja morbilidad de la BLC , el costo financiero adicional y el hecho de que no hay prácticamente ningún impacto en la decisión terapéutica invita a reflexionar sobre su real necesidad.Introdução: Os carcinomas in situ representam aproximadamente 15% dos cânceres de mama. Por definição, não ultrapassam a membrana basal, o que implicaria em um risco teórico nulo para metástase linfonodal. Entretanto, a literatura exibe taxas variando de 1% a 13% de metástases das biópsias de linfonodo sentinela (BLS) realizadas em pacientes com carcinoma ductal in situ (CDIS). Objetivo: Verificar a prevalência de metástase do linfonodo sentinela em pacientes com CDIS de mama, tratadas cirurgicamente numa instituição de referência no Nordeste Brasileiro. Método: Estudo transversal e descritivo, utilizando dados secundários, obtidos nos prontuários médicos de pacientes com câncer de mama, operadas no Instituto do Câncer do Ceará (ICC), entre os anos de 2002 a 2012. Os dados foram analisados por meio do software Epi Info 7.0. Resultados: A população de estudo correspondeu a 746 pacientes com tumor primário de mama, 106 (14%) apresentavam como tipo histológico inicial o CDIS. Cinquenta e quatro pacientes (51%) foram submetidas à mastectomia e 52 (49%) à cirurgia conservadora. A BLS foi realizada em 88 (83%) dos 106 casos com CDIS, apresentando positividade para metástase linfonodal em apenas um caso (1,1%). No fim da análise, das 106 pacientes com CDIS, duas apresentaram recidiva local, uma apresentou recidiva locorregional. Conclusão: A BLS em pacientes com CDIS puro, semelhante ao encontrado na literatura mundial, apresenta baixa prevalência de metástase linfonodal. Apesar da baixa morbidade da BLS, o custo financeiro adicional e o fato de praticamente não impactar na decisão terapêutica fazem refletir sobre sua real necessidade.INCA2015-03-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/75910.32635/2176-9745.RBC.2015v61n1.759Revista Brasileira de Cancerologia; Vol. 61 No. 1 (2015): Jan./Feb./Mar.; 37-42Revista Brasileira de Cancerologia; Vol. 61 Núm. 1 (2015): enero/feb./marzo; 37-42Revista Brasileira de Cancerologia; v. 61 n. 1 (2015): jan./fev./mar.; 37-422176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/759/489Souza, Helano de Paula GonçalvesCavalcante, Francisco PimentelFerreira, José Carlos Lucena de AguiarBatista, Rafael ValenteLima, Marcos Venício Alvesinfo:eu-repo/semantics/openAccess2021-11-29T20:09:06Zoai:rbc.inca.gov.br:article/759Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:09:06Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
¿La Biopsia del Ganglio Linfático Centinela en el Carcinoma Ductal in situ de Mama es Necesaria?
É Necessária a Biópsia do Linfonodo Sentinela no Carcinoma Ductal in situ da Mama?
title Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
spellingShingle Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
Souza, Helano de Paula Gonçalves
Biópsia de Linfonodo Sentinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
Sentinel Lymph Node Biopsy
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Biopsia del Ganglio Linfático Centinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
title_short Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
title_full Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
title_fullStr Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
title_full_unstemmed Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
title_sort Is Sentinel Lymph Node Biopsy Necessary in Ductal Breast Carcinoma in situ?
author Souza, Helano de Paula Gonçalves
author_facet Souza, Helano de Paula Gonçalves
Cavalcante, Francisco Pimentel
Ferreira, José Carlos Lucena de Aguiar
Batista, Rafael Valente
Lima, Marcos Venício Alves
author_role author
author2 Cavalcante, Francisco Pimentel
Ferreira, José Carlos Lucena de Aguiar
Batista, Rafael Valente
Lima, Marcos Venício Alves
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Souza, Helano de Paula Gonçalves
Cavalcante, Francisco Pimentel
Ferreira, José Carlos Lucena de Aguiar
Batista, Rafael Valente
Lima, Marcos Venício Alves
dc.subject.por.fl_str_mv Biópsia de Linfonodo Sentinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
Sentinel Lymph Node Biopsy
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Biopsia del Ganglio Linfático Centinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
topic Biópsia de Linfonodo Sentinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
Sentinel Lymph Node Biopsy
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Biopsia del Ganglio Linfático Centinela
Carcinoma Ductal de Mama
Carcinoma Intraductal não Infiltrante
description Introduction: Carcinoma in situ accounts for approximately 15% of breast cancers. By definition, it does not exceed the basal membrane, which would imply zero theoretical risk for lymph node metastasis. However, according to the literature, 1-13% of sentinel lymph node biopsies (SNB) in patients with carcinoma ductal in situ (DCIS) are positive. Objective: To determine the prevalence of sentinel lymph node metastasis in patients with DCIS treated surgically at a referral hospital in Northeastern Brazil. Method: Cross-sectional and descriptive study using secondary data obtained from the medical records of patients with breast cancer that underwent surgery at the Cancer Institute of Ceará (ICC) between 2002 and 2012. The data were analyzed with the software Epi Info 7.0. Results: The study population included 746 patients with primary breast tumors, being 106 (14%) of them diagnosed with DCIS on the initial histological examination. Fifty-four patients (51%) underwent mastectomy and 52 (49%) conservative surgery. SNB was performed in 88 (83%) of 106 cases of DCIS, but only one case (1.1%) was positive. During follow-up of the 106 DCIS patients, 2 had local recurrence and 1 had loco regional recurrence. Conclusion: SNB in patients with DCIS alone revealed a low prevalence of lymph node metastasis, matching most studies on the topic. Despite the low morbidity of SNB, the additional financial cost and its negligible impact on therapeutic decision suggest the procedure is not indispensable in this patient population.
publishDate 2015
dc.date.none.fl_str_mv 2015-03-31
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/759
10.32635/2176-9745.RBC.2015v61n1.759
url https://rbc.inca.gov.br/index.php/revista/article/view/759
identifier_str_mv 10.32635/2176-9745.RBC.2015v61n1.759
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/759/489
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 61 No. 1 (2015): Jan./Feb./Mar.; 37-42
Revista Brasileira de Cancerologia; Vol. 61 Núm. 1 (2015): enero/feb./marzo; 37-42
Revista Brasileira de Cancerologia; v. 61 n. 1 (2015): jan./fev./mar.; 37-42
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042245400002560